Tilray | TRLY - Ebit

Aktienkurs
8.99
Täglich Wechseln
-0.27 -2.92%
Monatlich
-9.83%
Jährlich
1,304.69%
Q2 Prognose
8.92




Ebit Veränderung Datum
Acasti Pharma USD -3.7M 1.13M 2024-12
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Alaunos Therapeutics USD -1.19M 148K 2025-09
Aurora Cannabis CAD -35.79M 8.96M 2025-12
Avita Medical AUD -10.39M 1.72M 2025-12
Canopy Growth CAD -12.66M 1.64M 2025-12
Cronos Group USD -7.06M 62.31M 2025-12
Dianthus Therapeutics USD -69.54M 29.25M 2025-12
Divis Laboratories Ltd INR 7.72B 30M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
IQVIA Holdings USD 2.68B 2.1B 2025-12
Knight Therapeutics CAD 6.21M 3.27M 2025-12
Moderna USD -857M 597M 2025-12
Organigram Holdings CAD -20.13M 7.92M 2025-12
Organon & Co USD 388M 28M 2025-09
Revvity USD 145.83M 47.49M 2025-12
Tectonic Therapeutic USD -21.52M 374K 2025-12
Tilray USD -20.01M 9.34M 2025-09
Viatris USD -157.5M 392M 2025-12
Xeris Pharmaceuticals USD 16.77M 8.88M 2025-12
Zealand Pharma A/S -707.05M 245.73M 2025-12